NR 566 FINAL EXAM NEWEST 2026 ACTUAL EXAM TEST
BANK| NR566 ADVANCED PHARMACOLOGY FOR CARE
OF THE FAMILY FINAL EXAM REVIEW WITH COMPLETE
250+ REAL EXAM QUESTIONS AND CORRECT DETAILED
ANSWERS (VERIFIED ANSWERS) ALREADY GRADED A+
(BRAND NEW!!)
TOPIC 1: PHARMACOKINETICS, PHARMACODYNAMICS &
DRUG INTERACTIONS (Questions 1–20)
Question 1: A drug with high first-pass metabolism is best administered via which route
to achieve systemic effect?
A. Oral
B. Sublingual
C. Intravenous
D. Rectal
Answer: C. Intravenous
Rationale: IV administration completely bypasses first-pass metabolism in the liver.
Sublingual and rectal routes partially avoid it, but IV is most reliable for drugs with
extensive first-pass metabolism.
,Question 2: Which cytochrome P450 enzyme is most commonly involved in clinically
significant drug interactions?
A. CYP1A2
B. CYP2C9
C. CYP3A4
D. CYP2E1
Answer: C. CYP3A4
Rationale: CYP3A4 metabolizes over 50% of all drugs, including statins,
benzodiazepines, and calcium channel blockers, making it the most common source of
drug interactions.
Question 3: A patient develops an exaggerated response to warfarin after starting
amiodarone. This interaction is most likely due to:
A. Increased renal excretion
B. P-gp induction
C. CYP2C9 inhibition
D. Increased protein binding
Answer: C. CYP2C9 inhibition
Rationale: Amiodarone inhibits CYP2C9, the enzyme responsible for metabolizing
warfarin. This inhibition leads to increased warfarin levels, prolonged INR, and increased
bleeding risk.
Question 4: A patient with a CYP2D6 genetic polymorphism (poor metabolizer) is
prescribed codeine. What is the primary concern?
,A. Increased risk of hepatotoxicity
B. Decreased analgesic effect due to reduced conversion to morphine
C. Increased risk of serotonin syndrome
D. No change in effect
Answer: B. Decreased analgesic effect
Rationale: Codeine requires CYP2D6 to convert it to its active metabolite, morphine.
Poor metabolizers experience inadequate pain relief due to reduced conversion.
Question 5: When adding a highly protein-bound (>95%) medication to a patient taking
warfarin, what is the primary concern?
A. Increased volume of distribution
B. Displacement leading to increased free warfarin and bleeding risk
C. Decreased renal clearance
D. Increased hepatic metabolism
Answer: B. Displacement leading to increased free warfarin and bleeding risk
Rationale: Highly protein-bound drugs can displace warfarin from albumin binding
sites, increasing the free (active) fraction of warfarin and potentiating its anticoagulant
effect.
Question 6: A medication has a narrow therapeutic index. This means:
A. The drug has a wide safety margin
B. Small changes in dose or blood level can cause toxicity
C. The drug is only effective in a narrow patient population
D. The drug must be given intravenously
, Answer: B. Small changes in dose or blood level can cause toxicity
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin, lithium) have a small
margin between therapeutic and toxic doses, requiring close monitoring.
Question 7: Which phase of pharmacokinetics describes the movement of a drug from
the bloodstream into tissues?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: B. Distribution
Rationale: Distribution is influenced by blood flow, protein binding, and tissue
permeability.
Question 8: Most drug metabolism occurs in which organ?
A. Kidney
B. Liver
C. Lungs
D. Skin
Answer: B. Liver
Rationale: The liver is the primary site of drug metabolism, containing the highest
concentration of drug-metabolizing enzymes, particularly cytochrome P450 enzymes.
BANK| NR566 ADVANCED PHARMACOLOGY FOR CARE
OF THE FAMILY FINAL EXAM REVIEW WITH COMPLETE
250+ REAL EXAM QUESTIONS AND CORRECT DETAILED
ANSWERS (VERIFIED ANSWERS) ALREADY GRADED A+
(BRAND NEW!!)
TOPIC 1: PHARMACOKINETICS, PHARMACODYNAMICS &
DRUG INTERACTIONS (Questions 1–20)
Question 1: A drug with high first-pass metabolism is best administered via which route
to achieve systemic effect?
A. Oral
B. Sublingual
C. Intravenous
D. Rectal
Answer: C. Intravenous
Rationale: IV administration completely bypasses first-pass metabolism in the liver.
Sublingual and rectal routes partially avoid it, but IV is most reliable for drugs with
extensive first-pass metabolism.
,Question 2: Which cytochrome P450 enzyme is most commonly involved in clinically
significant drug interactions?
A. CYP1A2
B. CYP2C9
C. CYP3A4
D. CYP2E1
Answer: C. CYP3A4
Rationale: CYP3A4 metabolizes over 50% of all drugs, including statins,
benzodiazepines, and calcium channel blockers, making it the most common source of
drug interactions.
Question 3: A patient develops an exaggerated response to warfarin after starting
amiodarone. This interaction is most likely due to:
A. Increased renal excretion
B. P-gp induction
C. CYP2C9 inhibition
D. Increased protein binding
Answer: C. CYP2C9 inhibition
Rationale: Amiodarone inhibits CYP2C9, the enzyme responsible for metabolizing
warfarin. This inhibition leads to increased warfarin levels, prolonged INR, and increased
bleeding risk.
Question 4: A patient with a CYP2D6 genetic polymorphism (poor metabolizer) is
prescribed codeine. What is the primary concern?
,A. Increased risk of hepatotoxicity
B. Decreased analgesic effect due to reduced conversion to morphine
C. Increased risk of serotonin syndrome
D. No change in effect
Answer: B. Decreased analgesic effect
Rationale: Codeine requires CYP2D6 to convert it to its active metabolite, morphine.
Poor metabolizers experience inadequate pain relief due to reduced conversion.
Question 5: When adding a highly protein-bound (>95%) medication to a patient taking
warfarin, what is the primary concern?
A. Increased volume of distribution
B. Displacement leading to increased free warfarin and bleeding risk
C. Decreased renal clearance
D. Increased hepatic metabolism
Answer: B. Displacement leading to increased free warfarin and bleeding risk
Rationale: Highly protein-bound drugs can displace warfarin from albumin binding
sites, increasing the free (active) fraction of warfarin and potentiating its anticoagulant
effect.
Question 6: A medication has a narrow therapeutic index. This means:
A. The drug has a wide safety margin
B. Small changes in dose or blood level can cause toxicity
C. The drug is only effective in a narrow patient population
D. The drug must be given intravenously
, Answer: B. Small changes in dose or blood level can cause toxicity
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin, lithium) have a small
margin between therapeutic and toxic doses, requiring close monitoring.
Question 7: Which phase of pharmacokinetics describes the movement of a drug from
the bloodstream into tissues?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: B. Distribution
Rationale: Distribution is influenced by blood flow, protein binding, and tissue
permeability.
Question 8: Most drug metabolism occurs in which organ?
A. Kidney
B. Liver
C. Lungs
D. Skin
Answer: B. Liver
Rationale: The liver is the primary site of drug metabolism, containing the highest
concentration of drug-metabolizing enzymes, particularly cytochrome P450 enzymes.
